太景醫藥研發控股股份有限公司
該股 RSI(6) 為 41.8,處於中性區間,短線無明顯超買超賣訊號。股價站上5日均線,跌破20日、60日、120日均線。短中期均線呈空頭排列,趨勢偏空。KD 指標中性(K=35.3);MACD 柱狀體為負值,空方動能持續。 (自動產生 · 非投資建議)
太景醫藥研發控股股份有限公司為新藥研發廠商,專注於治療具高度抗藥性之細菌感染與病毒性疾病。主要產品包括抗生素「太捷信(奈諾沙星)」及抗流感與抗 C 肝等臨床開發中藥物。公司成立於 2001 年,總部位於台灣台北。
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 11-10 | +27 | 0 | 0 | +27 |
| 11-09 | +95 | 0 | 0 | +95 |
| 11-06 | +90 | 0 | 0 | +90 |
| 11-05 | -132 | 0 | 0 | -132 |
| 11-04 | -24 | 0 | 0 | -24 |
| 11-03 | -210 | 0 | 0 | -210 |
| 11-02 | +42 | 0 | 0 | +42 |
| 10-30 | -201 | 0 | 0 | -201 |
| 10-29 | +105 | 0 | 0 | +105 |
| 10-28 | +44 | 0 | 0 | +44 |
| 10-27 | -268 | 0 | 0 | -268 |
| 10-22 | -81 | 0 | 0 | -81 |
| 10-21 | +283 | 0 | 0 | +283 |
| 10-20 | +394 | 0 | 0 | +394 |
| 10-19 | -289 | 0 | -2 | -291 |
| 10-16 | +410 | 0 | +2 | +412 |
| 10-15 | +12 | 0 | 0 | +12 |
| 10-14 | +75 | 0 | 0 | +75 |
| 10-13 | -176 | 0 | 0 | -176 |
| 10-12 | -780 | 0 | +1 | -779 |
| 10-08 | +337 | 0 | 0 | +337 |
| 10-07 | +342 | 0 | 0 | +342 |
| 10-06 | -9 | 0 | 0 | -9 |
| 10-05 | -571 | 0 | 0 | -571 |
| 10-02 | -300 | 0 | -1 | -301 |
| 10-01 | -133 | 0 | -1 | -134 |
| 09-30 | +401 | 0 | 0 | +401 |
| 09-29 | -304 | 0 | 0 | -304 |
| 09-24 | -167 | 0 | 0 | -167 |
| 09-23 | +606 | 0 | +1 | +607 |
| 09-22 | -208 | 0 | 0 | -208 |
| 09-21 | +19 | 0 | 0 | +19 |
| 09-18 | +12 | 0 | +1 | +13 |
| 09-17 | +502 | 0 | -1 | +501 |
| 09-16 | +141 | 0 | 0 | +141 |
| 09-15 | +341 | 0 | 0 | +341 |
| 09-14 | +22 | 0 | 0 | +22 |
| 09-11 | -296 | 0 | 0 | -296 |
| 09-10 | +23 | 0 | 0 | +23 |
| 09-09 | +273 | 0 | 0 | +273 |
| 09-08 | +27 | 0 | -2 | +26 |
| 09-07 | +99 | 0 | 0 | +99 |
| 09-04 | +49 | 0 | +1 | +50 |
| 09-03 | +58 | 0 | 0 | +58 |
| 09-02 | +98 | 0 | -1 | +97 |
| 09-01 | -87 | 0 | 0 | -87 |
| 08-31 | -151 | 0 | +1 | -150 |
| 08-28 | +399 | 0 | +1 | +400 |
| 08-27 | +327 | 0 | -1 | +326 |
| 08-26 | -61 | 0 | -1 | -62 |
| 08-25 | +76 | 0 | +1 | +77 |
| 08-24 | +5 | 0 | +6 | +11 |
| 08-21 | -185 | 0 | 0 | -185 |
| 08-20 | +410 | 0 | +1 | +411 |
| 08-19 | +84 | 0 | 0 | +84 |
| 08-18 | +187 | 0 | +1 | +188 |
| 08-17 | -73 | 0 | 0 | -73 |
| 08-14 | -442 | 0 | 0 | -443 |
| 08-13 | +107 | 0 | 0 | +107 |
| 08-12 | -24 | 0 | 0 | -24 |
| 08-11 | +463 | 0 | 0 | +463 |
| 08-10 | +117 | 0 | +1 | +118 |
| 08-07 | +229 | 0 | 0 | +229 |
| 08-06 | -81 | 0 | +1 | -80 |
| 08-05 | -110 | 0 | 0 | -110 |
| 08-04 | +189 | 0 | 0 | +189 |
| 08-03 | -64 | 0 | +1 | -64 |
| 07-31 | +117 | 0 | 0 | +117 |
| 07-30 | +170 | 0 | 0 | +170 |
| 07-29 | +160 | 0 | 0 | +160 |
| 07-28 | -7 | 0 | -1 | -8 |
| 07-27 | +12 | 0 | +1 | +13 |
| 07-24 | -53 | 0 | +1 | -52 |
| 07-23 | -205 | 0 | -1 | -206 |
| 07-22 | +340 | 0 | 0 | +340 |
| 07-21 | -70 | 0 | 0 | -70 |
| 07-20 | +294 | 0 | 0 | +293 |
| 07-17 | -299 | 0 | 0 | -299 |
| 07-16 | -3 | 0 | 0 | -3 |
| 07-15 | +43 | 0 | -1 | +42 |
| 07-14 | +86 | 0 | +1 | +87 |
| 07-13 | -199 | 0 | 0 | -199 |
| 07-09 | +29 | 0 | 0 | +29 |
| 07-08 | +22 | 0 | 0 | +22 |
| 07-07 | +254 | 0 | 0 | +254 |
| 07-06 | -330 | 0 | 0 | -330 |
| 07-03 | -348 | 0 | 0 | -348 |
| 07-02 | -285 | 0 | +1 | -285 |
| 07-01 | +197 | 0 | -2 | +195 |
| 06-30 | -84 | 0 | +2 | -82 |
| 06-29 | +341 | 0 | 0 | +341 |
| 06-26 | -299 | 0 | -5 | -304 |
| 06-25 | -55 | 0 | +1 | -55 |
| 06-24 | +730 | 0 | -1 | +729 |
| 06-23 | +31 | 0 | -6 | +25 |
| 06-22 | -263 | 0 | -5 | -267 |
| 06-18 | +42 | 0 | -3 | +39 |
| 06-17 | +6 | 0 | -1 | +5 |
| 06-16 | -392 | 0 | -12 | -404 |
| 06-15 | -48 | 0 | -2 | -50 |
| 06-12 | +466 | 0 | -1 | +465 |
| 06-11 | -74 | 0 | 0 | -74 |
| 06-10 | +56 | 0 | -14 | +42 |
| 06-09 | -589 | 0 | 0 | -589 |
| 06-08 | -564 | 0 | +49 | -515 |
| 06-05 | -607 | 0 | -2 | -609 |
| 06-04 | +530 | 0 | 0 | +529 |
| 06-03 | +497 | 0 | -3 | +494 |
| 06-02 | -310 | 0 | 0 | -310 |
| 06-01 | -350 | 0 | 0 | -350 |
| 05-29 | +469 | 0 | +2 | +471 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/10 | 525 萬 | +66.6% | +60.2% |
| 2026/09 | 315 萬 | -55.3% | +212.8% |
| 2026/08 | 705 萬 | +138.6% | +172.2% |
| 2026/07 | 296 萬 | -2.2% | -4.0% |
| 2026/06 | 302 萬 | +3.4% | -7.1% |
| 2026/05 | 292 萬 | +28.2% | -22.7% |
| 2026/04 | 228 萬 | +57.6% | -37.8% |
| 2026/03 | 145 萬 | -49.3% | -55.9% |
| 2026/02 | 285 萬 | -52.7% | -15.5% |
| 2026/01 | 604 萬 | -97.3% | +43.0% |
| 2025/12 | 2.24 億 | +5327.1% | +6482.8% |
| 2025/11 | 412 萬 | - | +30.8% |